Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent's sNDA for Use of PD-1 in NSCLC Accepted for China Review

publication date: Apr 24, 2020

Suzhou Innovent announced China's NMPA will review its sNDA for a combination regimen including the company's PD-1 antibody, Tyvyt®, to treat non-squamous non-small cell lung cancer. In late 2018, Tyvyt was approved for China use in patients with r/r classical Hodgkin's lymphoma. In a China Phase III trial, a combination of Tyvyt, Alimta® and platinum chemotherapy increased progression-free survival to a median of 8.9 months from 5 months for the other two drugs by themselves. Based on the data, the trial was stopped early. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.